The RSVChoice Study

Project status: Active

Research area: Infection, Immunity and Global Health > Vaccine Uptake

This study will explore parent decision-making around a maternal vaccine and medication to prevent Respiratory Syncytial Virus (RSV) in infants under 24 months that is being considered for use in Australia.

Overview

Respiratory Syncytial Virus (RSV) is a common, contagious respiratory virus that can cause severe infection in infants and children. In Australia, 95 per cent of hospitalisations due to RSV are in children under five years, with infants under two months having the highest rates of hospitalisation. Despite this, there is currently no vaccine to protect against RSV.

The RSVChoice Study will explore parent decision-making around a new maternal vaccine and medication to prevent Respiratory Syncytial Virus (RSV) in infants under 24 months, which will hopefully be available soon.

Parents in Australia will most likely face a choice between receiving an RSV vaccine during pregnancy or giving their infant a medication called a monoclonal antibody after they are born.

The study's first phase will include focus group discussions with mothers who have an infant under 24 months to understand what factors may inform their choice. A focus group is a semi-structured conversation with five to seven individuals on a topic of interest. These discussions will inform a survey to understand parental decision-making around future RSV vaccines and medicines.

Information for participants

Who can take part?

Mothers with an infant under 24 months living in Australia
Mothers who can attend a 1-1.5 hour focus group online

What happens in the study?

Participation will include attending a focus group to discuss future vaccines and medications that may prevent RSV
You will receive a $30 gift card to thank you for your time

Contact us

RSVChoice Study
Murdoch Children's Research Institute
The Royal Children's Hospital
50 Flemington Road
Parkville VIC 3052
Australia

Email: show email address